FDA Clearance Tracker · DEN240068
ArteraAI Prostate
Last checked: Nov 20, 2026Latest source record: Jul 31, 2025 (this decision)Source: openFDAMethods & limitations
Decided
Jul 31, 2025
De Novo granted
Time to decision
248 days
Received Nov 25, 2024. Calendar days, including time FDA spent waiting on the applicant.
Pathway
De Novo
Direct
Device class
Class II
The decision
- FDA number
- DEN240068
- Device name
- ArteraAI Prostate
- Applicant
- Artera, Inc.
- Applicant location
- Los Altos, CA
- Received
- Nov 25, 2024
- Decided
- Jul 31, 2025
- Decision
- De Novo granted
- Submission type
- Direct
Device type
- Device type
- Pathology Software Algorithm Device Analyzing Digital Images For Prostate Cancer Prognosis (SFH)
- Device class
- Class II
- Regulation
- 21 CFR 864.3755
- Specialty
- Laboratory Medicine & Pathology
How new is this?
These are facts about FDA's records. They are not a judgment about the device.
- FDA granted this as a De Novo request, which means it created a new device type. There was no existing device to compare it to.
- It is on FDA's public list of Breakthrough Devices with marketing authorization (list dated June 30, 2026).
Source documents
- FDA database record for DEN240068
- Decision summary (PDF) · FDA posts these some weeks after the decision, so a recent one may not open yet.
Other decisions for Artera, Inc.
Matched on the applicant name as FDA recorded it. A company that files under several names will have more.
- ArteraAI Breast510(k)
K254115 · Decided May 4, 2026 · 136 days after receipt
Device type: Pathology Software Algorithm Device Analyzing Digital Images For Breast Cancer Prognosis (SHW) · Laboratory Medicine & Pathology
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.